# Alirocumab

## Praluent solution for injection 75mg

| TAH Drug Code      | [IPRA](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IPRA)                                                                                                                                                                                                                    |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Hyperlipidemia, primary: Adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C. Prevent cardiovascular events |
| Dosing             | 75 mg SC once every 2 weeks or 300 mg SC monthly. Maximum dose: 150 mg SC every 2 weeks.                                                                                                                                                                                                |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                           |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                           |
| Contraindications  | Hypersensitivity.                                                                                                                                                                                                                                                                       |
| Adverse Effects    | Common: Injection site disorder (3.8-16.6%), Nasopharyngitis (6-11.3%), Influenza (5.7%) Serious: Hypersensitivity reaction (8.6%), Angioedema                                                                                                                                          |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                         |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                           |

